Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets

Ann Rheum Dis. 2023 Aug;82(8):999-1014. doi: 10.1136/ard-2022-223741. Epub 2023 Feb 15.

Abstract

Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins, as fundamental contributors to the disease. On the fertile background of significant genetic risk, a triggering stimulus, perhaps microbial, induces IFN-I, autoantibody production or most likely both. When innate and adaptive immune system cells are engaged and collaborate in the autoimmune response, clinical SLE can develop. This review describes recent data from genetic analyses of patients with SLE, along with current studies of innate and adaptive immune function that contribute to sustained IFN-I pathway activation, immune activation and autoantibody production, generation of inflammatory mediators and tissue damage. The goal of these studies is to understand disease mechanisms, identify therapeutic targets and stimulate development of therapeutics that can achieve improved outcomes for patients.

Keywords: Autoantibodies; Autoimmunity; Cytokines; Lupus Erythematosus, Systemic; Polymorphism, Genetic.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Humans
  • Interferon Type I* / metabolism
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Erythematosus, Systemic* / genetics

Substances

  • Autoantibodies
  • Interferon Type I